Soft Zejula sales, guidance sink Tesaro shares

Tesaro Inc. (NASDAQ:TSRO) slipped $6.32 (10%) to $55.23 on Wednesday after reporting lower-than-anticipated 4Q17 revenue and 2018 guidance for its PARP inhibitor Zejula niraparib. The company announced quarterly and full-year earnings after market close on Tuesday.

Zejula sales were $43.4 million in 4Q17, short of the consensus $45.9 million estimate. The company guided to 2018 Zejula sales of $255-$275 million, below the $307 million consensus...